These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

495 related articles for article (PubMed ID: 31345380)

  • 1. Cisplatin and oxaliplatin induce similar immunogenic changes in preclinical models of head and neck cancer.
    Park SJ; Ye W; Xiao R; Silvin C; Padget M; Hodge JW; Van Waes C; Schmitt NC
    Oral Oncol; 2019 Aug; 95():127-135. PubMed ID: 31345380
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cisplatin Alters Antitumor Immunity and Synergizes with PD-1/PD-L1 Inhibition in Head and Neck Squamous Cell Carcinoma.
    Tran L; Allen CT; Xiao R; Moore E; Davis R; Park SJ; Spielbauer K; Van Waes C; Schmitt NC
    Cancer Immunol Res; 2017 Dec; 5(12):1141-1151. PubMed ID: 29097421
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Statin in combination with cisplatin makes favorable tumor-immune microenvironment for immunotherapy of head and neck squamous cell carcinoma.
    Kwon M; Nam GH; Jung H; Kim SA; Kim S; Choi Y; Lee YS; Cho HJ; Kim IS
    Cancer Lett; 2021 Dec; 522():198-210. PubMed ID: 34571082
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The EXTREME Regimen Associating Cetuximab and Cisplatin Favors Head and Neck Cancer Cell Death and Immunogenicity with the Induction of an Anti-Cancer Immune Response.
    De Azevedo J; Mourtada J; Bour C; Devignot V; Schultz P; Borel C; Pencreach E; Mellitzer G; Gaiddon C; Jung AC
    Cells; 2022 Sep; 11(18):. PubMed ID: 36139440
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Tumor hypoxia is associated with resistance to PD-1 blockade in squamous cell carcinoma of the head and neck.
    Zandberg DP; Menk AV; Velez M; Normolle D; DePeaux K; Liu A; Ferris RL; Delgoffe GM
    J Immunother Cancer; 2021 May; 9(5):. PubMed ID: 33986123
    [TBL] [Abstract][Full Text] [Related]  

  • 6. HPV16 E5 Mediates Resistance to PD-L1 Blockade and Can Be Targeted with Rimantadine in Head and Neck Cancer.
    Miyauchi S; Sanders PD; Guram K; Kim SS; Paolini F; Venuti A; Cohen EEW; Gutkind JS; Califano JA; Sharabi AB
    Cancer Res; 2020 Feb; 80(4):732-746. PubMed ID: 31848196
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Ammonium tetrathiomolybdate enhances the antitumor effect of cisplatin via the suppression of ATPase copper transporting beta in head and neck squamous cell carcinoma.
    Ryumon S; Okui T; Kunisada Y; Kishimoto K; Shimo T; Hasegawa K; Ibaragi S; Akiyama K; Thu Ha NT; Monsur Hassan NM; Sasaki A
    Oncol Rep; 2019 Dec; 42(6):2611-2621. PubMed ID: 31638244
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Targeting EZH2 Enhances Antigen Presentation, Antitumor Immunity, and Circumvents Anti-PD-1 Resistance in Head and Neck Cancer.
    Zhou L; Mudianto T; Ma X; Riley R; Uppaluri R
    Clin Cancer Res; 2020 Jan; 26(1):290-300. PubMed ID: 31562203
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The Evolving Landscape of PD-1/PD-L1 Pathway in Head and Neck Cancer.
    Qiao XW; Jiang J; Pang X; Huang MC; Tang YJ; Liang XH; Tang YL
    Front Immunol; 2020; 11():1721. PubMed ID: 33072064
    [TBL] [Abstract][Full Text] [Related]  

  • 10.
    Nazari F; Oklejas AE; Nör JE; Pearson AT; Jackson TL
    Cancer Res; 2020 Apr; 80(7):1451-1460. PubMed ID: 32041834
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Unveiling the regulatory mechanism of nimotuzumab on PD-L1 expression in head and neck squamous cell carcinoma patients: Implications for enhanced anticancer treatment strategies.
    Hu M; Tang B; Dai Y; Zhao X
    Cell Signal; 2024 Sep; 121():111290. PubMed ID: 38977231
    [TBL] [Abstract][Full Text] [Related]  

  • 12. ATR inhibition sensitizes HPV
    Leonard BC; Lee ED; Bhola NE; Li H; Sogaard KK; Bakkenist CJ; Grandis JR; Johnson DE
    Oral Oncol; 2019 Aug; 95():35-42. PubMed ID: 31345392
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Optimizing treatments for recurrent or metastatic head and neck squamous cell carcinoma.
    Specenier P; Vermorken JB
    Expert Rev Anticancer Ther; 2018 Sep; 18(9):901-915. PubMed ID: 29999437
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Enhancing programmed cell death protein 1 axis inhibition in head and neck squamous cell carcinoma: Combination immunotherapy.
    Vathiotis IA; Johnson JM; Argiris A
    Cancer Treat Rev; 2021 Jun; 97():102192. PubMed ID: 33819755
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Immunotherapy in recurrent and or metastatic squamous cell carcinoma of the head and neck.
    Saada-Bouzid E; Peyrade F; Guigay J
    Curr Opin Oncol; 2019 May; 31(3):146-151. PubMed ID: 30893146
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Interleukin-1 alpha increases anti-tumor efficacy of cetuximab in head and neck squamous cell carcinoma.
    Espinosa-Cotton M; Rodman Iii SN; Ross KA; Jensen IJ; Sangodeyi-Miller K; McLaren AJ; Dahl RA; Gibson-Corley KN; Koch AT; Fu YX; Badovinac VP; Laux D; Narasimhan B; Simons AL
    J Immunother Cancer; 2019 Mar; 7(1):79. PubMed ID: 30890189
    [TBL] [Abstract][Full Text] [Related]  

  • 17. PD-L1 and MRN synergy in platinum-based chemoresistance of head and neck squamous cell carcinoma.
    Shen B; Huang D; Ramsey AJ; Ig-Izevbekhai K; Zhang K; Lajud SA; O'Malley BW; Li D
    Br J Cancer; 2020 Mar; 122(5):640-647. PubMed ID: 31853007
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Interleukin 6 is increased in preclinical HNSCC models of acquired cetuximab resistance, but is not required for maintenance of resistance.
    O'Keefe RA; Bhola NE; Lee DS; Johnson DE; Grandis JR
    PLoS One; 2020; 15(1):e0227261. PubMed ID: 31914141
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Head and neck cancer organoids established by modification of the CTOS method can be used to predict in vivo drug sensitivity.
    Tanaka N; Osman AA; Takahashi Y; Lindemann A; Patel AA; Zhao M; Takahashi H; Myers JN
    Oral Oncol; 2018 Dec; 87():49-57. PubMed ID: 30527243
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Disruption of the HER3-PI3K-mTOR oncogenic signaling axis and PD-1 blockade as a multimodal precision immunotherapy in head and neck cancer.
    Wang Z; Goto Y; Allevato MM; Wu VH; Saddawi-Konefka R; Gilardi M; Alvarado D; Yung BS; O'Farrell A; Molinolo AA; Duvvuri U; Grandis JR; Califano JA; Cohen EEW; Gutkind JS
    Nat Commun; 2021 Apr; 12(1):2383. PubMed ID: 33888713
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 25.